Skip to main content
. 2020 Aug 22;12(9):2378. doi: 10.3390/cancers12092378

Table 1.

Details of the primers designed to validate CRISPR/Cas9 constructs (primer A and D) and genotype the exon-v6 skipping cell models obtained by CRISPR/Cas9 and Phosphorodiamidate Morpholino Oligomers (PMOs) approaches (primer B, C, E and F).

Orientation In-Text Name Binding Site Primer Sequence (5′–3′) Melting Temperature
Forward A pSpCas9(BB)_Bbs I 5′-GGGCCTATTTCCCATGATTCCTT-3′ Tm = 68.5 °C
B CD44 Exon 10 (v5) 5′-ATGTAGACAGAAATGGCACCAC-3′ Tm = 62.7 °C
C CD44 Intron 10 5′-ATCAGTGGCCTGTTTCCTTG-3′ Tm = 64.0 °C
Reverse D pSpCas9(BB)_Bbs I 5′-GACTCGGTGCCACTTTTTCAA-3′ Tm = 66.2 °C
E CD44 Exon 12 (v7) 5′-CCATCCTTCTTCCTGCTTGATG-3′ Tm = 66.8 °C
F CD44 Intron 11 5′-TTTGGCTCTGTGTGAACTGC-3′ Tm = 64.1 °C